glp-1 obesity drugs pipeline Transforming obesity: The advancement of multi-receptor drugs: Cell In 5 years, obesity drugs
Description
Interestingly, this study did not detect the expression of AXIN2, FZD4, TCF4, WNT5A, WNT3, WNT4, or WNT7A genes in the ovaries of either PCOS patients or healthy women (57)
PMID: 39535805
Also, widespread awareness among both clinicians and patients drives the expansion
After weekly subcutaneous injection, EX was slowly released from the microspheres by diffusion and microsphere rupture and reached a stable plasma concentration about 6-8 weeks after treatment (114)
